What is Royalty Pharma's long-term debt?

Royalty Pharma (RPRX) reported long-term debt of $8.58B in Q1 2026.

How has Royalty Pharma's long-term debt changed year-over-year?

Royalty Pharma's long-term debt increased by 29.6% year-over-year, from $6.62B to $8.58B.

What is the long-term trend for Royalty Pharma's long-term debt?

Over 5 years (2020 to 2025), Royalty Pharma's long-term debt has grown at a 8.1% compound annual growth rate (CAGR), from $5.82B to $8.57B.

What does long-term debt mean?

Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Royalty Pharma RPRX Long-Term Debt

Long-Term Debt at other companies

Rigel PharmaceuticalsRIGL

$45M—

Bristol-Myers SquibbBMY

$42.09B-5.3%

Innoviva, Inc.INVA

$258.1M+0.6%

BioCryst PharmaceuticalsBCRX

$395.2M+25.3%

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation

See full

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's long-term debt?: Royalty Pharma (RPRX) reported long-term debt of $8.58B in Q1 2026.
How has Royalty Pharma's long-term debt changed year-over-year?: Royalty Pharma's long-term debt increased by 29.6% year-over-year, from $6.62B to $8.58B.
What is the long-term trend for Royalty Pharma's long-term debt?: Over 5 years (2020 to 2025), Royalty Pharma's long-term debt has grown at a 8.1% compound annual growth rate (CAGR), from $5.82B to $8.57B.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.